Showing results (251-260 of 444) with videos related to

Sort By:
Pageof 45
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 22, 2005
Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndromeMark G Jones, C Stewart Goodwin, Saira Amjad, et al.
Current Opinion in Pulmonary Medicine|February 16, 2017
Personalized medicine in interstitial lung diseasesPaolo Spagnolo, Justin M Oldham, Mark G Jones, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 13, 2005
CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefactsRonald A Chalmers, Mark G Jones, C Stewart Goodwin, et al.
Chest|February 21, 2023
Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary FibrosisBhavika Kaul, Joyce S Lee, Laura A Petersen, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
Biomedicines|January 28, 2026
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel PathwaysLorenzo Carriera, Roberto Lipsi, Meridiana Dodaj, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
BMJ Open Respiratory Research|January 21, 2022
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trialZoran Popmihajlov, Donna J Sutherland, Gerald S Horan, et al.
Pageof 45